Avalo Therapeutics Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Avalo TherapeuticsDer Umsatz und der Gewinn des Unternehmens werden voraussichtlich um 89% bzw. 17.9% pro Jahr zurückgehen, während der Gewinn pro Aktie voraussichtlich um 39.8% pro Jahr wachsen wird.

Wichtige Informationen

-17.9%

Wachstumsrate der Gewinne

39.8%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	28.3%
Wachstumsrate der Einnahmen	-89.0%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	08 Nov 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Cerecor enters into $35M debt financing agreement with Horizon Technology Finance

Jun 07

What Kind Of Investors Own Most Of Cerecor Inc. (NASDAQ:CERC)?

Mar 10

Have Insiders Been Buying Cerecor Inc. (NASDAQ:CERC) Shares?

Jan 18

Armistice Capital adds 2.5M Cerecor shares for $6.5M

Jan 13

Cerecor slumps 12% on stock and pre-funded warrants offering

Jan 07

Gewinn- und Umsatzwachstumsprognosen

NasdaqCM:AVTX - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	N/A	-52	N/A	-35	2
12/31/2025	N/A	-51	N/A	-39	2
12/31/2024	0	-62	N/A	-40	2
9/30/2024	1	-8	-37	-37	N/A
6/30/2024	1	-19	-32	-32	N/A
3/31/2024	1	-49	-27	-27	N/A
12/31/2023	2	-32	-31	-31	N/A
9/30/2023	2	-33	-32	-32	N/A
6/30/2023	17	-25	-19	-19	N/A
3/31/2023	17	-30	-21	-21	N/A
12/31/2022	18	-42	-27	-27	N/A
9/30/2022	17	-51	-40	-40	N/A
6/30/2022	4	-72	-62	-62	N/A
3/31/2022	6	-76	-69	-69	N/A
12/31/2021	5	-84	-71	-71	N/A
9/30/2021	7	-81	-68	-68	N/A
6/30/2021	6	-77	-64	-64	N/A
3/31/2021	4	-73	-53	-53	N/A
12/31/2020	7	-64	-41	-41	N/A
9/30/2020	6	-54	-28	-28	N/A
6/30/2020	7	-44	-24	-24	N/A
3/31/2020	7	-33	-22	-22	N/A
12/31/2019	7	-16	-19	-19	N/A
9/30/2019	0	-13	-20	-19	N/A
6/30/2019	2	-35	-13	-12	N/A
3/31/2019	5	-38	-7	-6	N/A
12/31/2018	7	-37	-4	-3	N/A
9/30/2018	16	-42	-4	-4	N/A
6/30/2018	37	2	N/A	16	N/A
3/31/2018	32	6	N/A	15	N/A
12/31/2017	28	8	N/A	13	N/A
9/30/2017	26	13	N/A	11	N/A
6/30/2017	1	-12	N/A	-11	N/A
3/31/2017	2	-13	N/A	-13	N/A
12/31/2016	1	-16	N/A	-15	N/A
9/30/2016	1	-18	N/A	-14	N/A
6/30/2016	1	-13	N/A	-13	N/A
3/31/2016	N/A	-12	N/A	-11	N/A
12/31/2015	N/A	-10	N/A	-10	N/A
9/30/2015	N/A	3	N/A	-11	N/A
6/30/2015	N/A	-2	N/A	-16	N/A
3/31/2015	N/A	-3	N/A	-16	N/A
12/31/2014	N/A	-4	N/A	-16	N/A
9/30/2014	N/A	-17	N/A	-14	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: AVTX wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: AVTX wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: AVTX wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: AVTXDie Einnahmen des Unternehmens werden in den nächsten 3 Jahren voraussichtlich zurückgehen (-89% pro Jahr).

Hohe Wachstumseinnahmen: AVTXDie Einnahmen des Unternehmens werden in den nächsten drei Jahren voraussichtlich zurückgehen (-89% pro Jahr).

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von AVTX in 3 Jahren voraussichtlich hoch sein wird

Avalo Therapeutics Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Price target decreased by 93% to US$0.75

Consensus revenue estimates decrease by 79%, EPS upgraded

Consensus revenue estimates decrease by 79%, EPS upgraded

Consensus revenue estimates increase by 43%

Consensus forecasts updated

Forecast to breakeven in 2024

Recent updates

Avalo Therapeutics, Inc. Announces First Patient Dosed in Phase 2 Lotus Trial of Avtx-009 for the Treatment of Hidradenitis Suppurativa

Avalo Therapeutics, Inc. Appoints Mittie Doyle as Chief Medical Officer

Avalo Therapeutics Announces Active IND for AVTX-009, an Anti-IL-1ß mAb, to Treat Hidradenitis Suppurativa

Avalo Therapeutics, Inc., Annual General Meeting, Aug 13, 2024

Avalo Therapeutics, Inc. Appoints Paul Varki as Chief Legal Officer

Avalo Therapeutics Receives Notice from the Listing Qualifications Department of the Nasdaq Stock Market Regarding Stockholders' Equity Requirement

Avalo Therapeutics, Inc. Announces Board Appointments

Hearings Panel Grants Avalo Therapeutics an Exception from Compliance with the MVLS Rule and the Bid Price Rule and Extension of Continued Listing Until December 29, 2023

Avalo Therapeutics, Inc., Annual General Meeting, Dec 05, 2023

Nasdaq Determines to Delist Securities of Avalo Therapeutics

AUG Therapeutics, LLC entered into a purchase agreement to acquire rights, title and interest in, assets relating to AVTX-800 Series from Avalo Therapeutics, Inc. (NasdaqCM:AVTX).

Avalo Therapeutics, Inc. Receives Notice from Nasdaq Regarding Bid Price Rule

New major risk - Shareholder dilution

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

New minor risk - Insider selling

New major risk - Market cap size

Price target decreased by 93% to US$0.75

Avalo Announces Topline Data from Phase 2 Peak Trial for Avtx-002 (Quisovalimab) in Patients with Non-Eosinophilic Asthma

Insider recently bought US$56k worth of stock

Insider recently bought US$89k worth of stock

Consensus revenue estimates decrease by 79%, EPS upgraded

Consensus revenue estimates decrease by 79%, EPS upgraded

Insider recently bought US$69k worth of stock

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Insider recently bought US$143k worth of stock

Full year 2022 earnings: Revenues miss analyst expectations

Avalo Therapeutics, Inc. has completed a Follow-on Equity Offering.

Avalo Therapeutics, Inc. has completed a Follow-on Equity Offering.

Avalo Therapeutics, Inc. Completes Targeted Enrollment of 80 Patients in Phase 2 PEAK Trial of AVTX-002 in Non-Eosinophilic Asthma

Consensus revenue estimates increase by 43%

Consensus forecasts updated

Forecast to breakeven in 2024

Forecast to breakeven in 2024

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Avalo Therapeutics, Inc. Advances B and T Lymphocyte Attenuator Agonist Fusion Protein (AVTX-008) to IND-Enabling Stage

High number of new and inexperienced directors

Avalo Therapeutics Announces Board Changes

Consensus revenue estimates increase by 190%

Price target decreased to US$11.38

Price target increased to US$53.67

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Avalo Therapeutics Announces First Patient Dosed in the AVTX-803 Pivotal Trial (LADDER) for the Treatment of Leukocyte Adhesion Deficiency Type II (LAD II)

Price target decreased to US$30.00

Avalo to get ~15M upfront in license deal with Apollo Therapeutics for AVTX-007

Consensus revenue estimates fall by 10%

Price target decreased to US$43.50

Avalo Therapeutics announces one-for-twelve reverse stock split

Consensus forecasts updated

Avalo Therapeutics, Inc. Announces First Patient Dosed in the Phase 2 PEAK Trial of AVTX-002 for the Treatment of Non-Eosinophilic Asthma

Consensus forecasts updated

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target decreased to US$3.95

Avalo Therapeutics, Inc., Annual General Meeting, Jun 14, 2022

Price target decreased to US$3.95

Full year 2021 earnings: Revenues miss analyst expectations

Avalo Therapeutics, Inc. Announces Executive and Board Changes

Avalo Therapeutics, Inc. Announces Chief Executive Officer Changes

Avalo Therapeutics, Inc. Announces Resignation of H. Jeffrey Wilkins as Chief Medical Officer

Price target decreased to US$5.75

Avalo Therapeutics, Inc. Reports Positive Phase 1b Results for AVTX-002 in Moderate to Severe Crohn's Disease Patients and Presents Additional Program Updates at 2022 Investor Event

Third quarter 2021 earnings released: US$0.17 loss per share (vs US$0.16 loss in 3Q 2020)

Price target decreased to US$6.00

Avalo Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $27.5 million.

Avalo Therapeutics, Inc.(NasdaqCM:AVTX) dropped from NASDAQ Composite Index

Is Cerecor (NASDAQ:CERC) A Risky Investment?

Consensus forecasts updated

Second quarter 2021 earnings released: US$0.88 loss per share (vs US$0.19 loss in 2Q 2020)

High number of new directors

Price target decreased to US$6.80